

Publications 2002 - 2005

Classées par ordre d'IF 2005 décroissant des journaux

Publications originales

2002

1. The Eurohepygast Study Group (Project leader: F. Mégraud). Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study. *Gut* 2002; 50: 779-785. (IF 7.692)
2. Broutet, N., Moran, A., Hynes, S., Sakarovitch, C., Mégraud, F. Lewis antigen expression and other pathogenic factors in the presence of atrophic chronic gastritis in a European population. *Journal of Infectious Diseases* 2002; 185: 503-512. (IF 4.953)
3. Ménard, A., Santos, A., Mégraud, F., Oleastro, M. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with *Helicobacter pylori* resistance to clarithromycin. *Antimicrobial Agents and Chemotherapy* 2002; 46: 1156-1157. (IF 4.379)
4. Bégueret, H., Vergier, B., Parrens, M., Lehours, P., Laurent, F., Vernejoux, J.M., Dubus, P., Velly, J.F., Mégraud, F., Taytard, A., Merlio, J.P., de Mascarel, A. Primary lung small B-cell lymphoma versus lymphoid hyperplasia : evaluation of diagnostic criteria in 26 cases. *American Journal of Surgical Pathology* 2002; 26: 76-81. (IF 4.377)
5. Matysiak-Budnik, T., Heyman, M., Candalh, C., Lethuaire, D., Mégraud, F. *In vitro* transfer of clarithromycin and amoxicillin across the epithelial barrier. *Journal of Antimicrobial Chemotherapy* 2002; 50: 865-872. (IF 3.886)
6. Salles-Montaudon, N., Dertheil, S., Broutet, N., Gras, N., Monteiro, L., de Mascarel, A., Mégraud, F., Emeriau, J.P. Detecting *Helicobacter pylori* infection in hospitalized frail older patients: the challenge. *Journal of the American Geriatric Society* 2002; 50: 1674-1680. (IF 3.479)
7. Malfertheiner, P., Mégraud, F., O'Morain, C., Hungin, P., Jones, R., Axon, A., Graham, D.Y., Tytgat, G., & the European *Helicobacter pylori* Study Group (EHPSG). Current concepts in the management of *Helicobacter pylori* infection – The Maastricht 2-2000 Consensus Report. *Alimentary Pharmacology & Therapeutics* 2002; 16: 167-180. (IF 3.434)
8. Chanto, G., Occhialini, A., Gras, N., Alm, R.A., Mégraud, F., Marais, A. Identification of strain-specific genes located outside the plasticity zone in nine clinical isolates of *Helicobacter pylori*. *Microbiology* 2002; 148: 3671-3680. (IF 3.173)
9. Monteiro, L., Bergey, B., Gras, N., Mégraud, F. Evaluation of the performance of the Helico Blot 2.1 as a tool to investigate the virulence properties of *Helicobacter pylori*. *Clinical Microbiology & Infection* 2002; 8: 676-679. (IF 2.679)

10. Grignon, B., Tankovic, J., Mégraud, F., Glupczynski, Y., Husson, M.O., Conroy, M.C., Emond, J.P., Loulergue, J., Raymond, J., Fauchère, J.L. Validation of diffusion methods for macrolide susceptibility testing of *Helicobacter pylori*. *Microbial Drug Resistance* 2002; 8: 61-66. (IF 2.072)
11. Glupczynski, Y., Broutet, N., Cantagrel, A., Andersen, L.P., Alarcon, T., Lopez-Brea, M., Mégraud, F. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of *Helicobacter pylori*. *European Journal of Clinical Microbiology & Infectious Diseases* 2002; 21: 549-552. (IF 2.061)
12. Aguejoug, O., Mayo, K., Monteiro, L., Doutremepuich, F., Doutremépuich, C., Mégraud, F. Increase of arterial thrombosis parameters in chronic *Helicobacter pylori* infection in mice. *Thrombosis Research* 2002; 108: 245-248. (IF 2.012)
13. Nylen, G., Dunstan, F., Palmer, S., Andersson, Y., Bager, F., Cowden, J., Geierl, G., Galloway, Y., Kapperud, G., Mégraud, F., Molbak, K., Petersen, L.R., Ruutu, P. The seasonal distribution of campylobacter infection in nine European countries and New Zealand. *Epidemiology & Infection* 2002; 128: 383-390. (IF 1.674)
14. Weill, F.X., Margeridon, S., Broutet, N., Le Hello, S., Neyret, C., Mégraud, F. Seroepidemiology of *Helicobacter pylori* infection in Guadeloupe. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2002; 96: 517-519. (IF 1.665)
15. Matysiak-Budnik, T., Mégraud, F., Heyman, M. In-vitro transfer of nitazoxanide across the intestinal epithelial barrier. *Journal of Pharmacy and Pharmacology* 2002; 54: 1413-1417. (IF 1.396)
16. Smith, S., Cantet, F., Angelini, F. Marais, A., Mégraud, F., Bayerdöffer, E., Miehle, S. Discriminatory power of RAPD, PCR-RFLP and Southern Blot analyses of *ureCD* or *ureA* gene probes on *Helicobacter pylori* isolates. *Zeitschrift für Naturforschung* 2002;57c:516-521.

2003

17. Falush, D., Wirth, T., Linz, B., Pritchard, J.K., Stephens, M., Kidd, M., Blaser, M.J., Graham, D.Y., Vacher, S., Perez-Perez, G.I., Yamaoka, Y., Mégraud, F., Otto, K., Reichard, U., Katzowitsch, E., Wang, X., Achtman, M., Suerbaum, S. Traces of human migrations in *Helicobacter pylori* populations. *Science* 2003; 299: 1582-1585. (IF 30.927)
18. Lehours, P., Ruskone-Fourmestreaux, A., Lavergne, A., Cantet, F., Mégraud, F, Groupe d'Etude des Lymphomes Digestifs (GELD) for the Fédération Française de Cancérologie Digestive (FFCD). Which test to use to detect *H. pylori* infection in patients with low grade gastric MALT lymphoma? *American Journal of Gastroenterology* 2003; 98: 291-295. (IF 5.116)
19. Vacher S., Ménard, A., Bernard, E., Mégraud, F. PCR-restriction fragment length polymorphism analysis for detection of point mutations associated with macrolide resistance in *Campylobacter* spp. *Antimicrobial Agents & Chemotherapy* 2003; 47: 1125-1128. (IF 4.379)

20. Broutet, N., Plebani, M., Sakarovitch, C., Sipponen, P., Mégraud, F., Eurohepygast Study Group. Pepsinogen A, pepsinogen C and gastrin as markers of atrophic chronic gastritis in European dyspeptics. *British Journal of Cancer* 2003; 88: 1239-1247. (IF 4.115)
21. Avenaudo, P., LeBail, B., Marais, A., Mayo, K., Marais, A., Fawaz, R., Bioulac-Sage, P., Mégraud, F. Natural history of *Helicobacter hepaticus* infection in conventional A/J mice, with special reference to liver involvement. *Infection and Immunity* 2003; 71: 3667-3672. (IF 3.933)
22. Matysiak-Budnik, T., van Niel, G., Mégraud, F., Mayo, K., Bevilacqua, C., Gaboriau-Routhiau, V., Moreau, M.C., Heyman, M. Gastric *Helicobacter* infection inhibits development of oral tolerance to food antigens in mice. *Infection and Immunity* 2003; 71: 5219-5224. (IF 3.933)
23. Oleastro, M., Ménard, A., Santos, A., Lamouliatte, H., Monteiro, L., Barthélémy, C., Mégraud, F. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in *Helicobacter pylori*. *Journal of Clinical Microbiology* 2003; 41: 397-402. (IF 3.537)
24. Santos, A., Queiroz, D.M.M., Ménard, A., Marais, A., Rocha, G.A., Oliveira, C.A., Nogueira, A.M.M.F., Uzeda, M., Mégraud, F. New pathogenicity marker found in the plasticity region of the *Helicobacter pylori* genome. *Journal of Clinical Microbiology* 2003; 41: 1651-1655. (IF 3.537)
25. Broutet, N., Tchamgoué, S., Periera, E., Lamouliatte, H., Salamon, R., Mégraud, F. Risk factors for failure of *Helicobacter pylori* therapy - results of an individual data analysis of 2751 patients. *Alimentary Pharmacology & Therapeutics* 2003; 17: 99-109. (IF 3.434)
26. O'Morain, C., Borody, T., Farley, A., de Boer, W., Dallaire, C., Schuman, R., Piotrowskii, J., Fallone, C.A., Tytgat, G., Mégraud, F., Spénard, J. Efficacy and safety of single triple capsule of bismuth biscaltrate, metronidazole, and tetracycline given with omeprazole for eradication of *Helicobacter pylori*: international multicentre study. *Alimentary Pharmacology & Therapeutics* 2003; 17: 415-420. (IF 3.434)
27. Bergey, B., Marchildon, P., Peacock, J., Mégraud, F. What is the role of serology in assessing *Helicobacter pylori* eradication. *Alimentary Pharmacology & Therapeutics* 2003; 18: 635-639. (IF 3.434)
28. Lamouliatte, H., Mégraud, F., Delchier, J.C., Bretagne, J.F., Courillon-Mallet, A., de Korwin, J.D., Fauchère, J.L., Labigne, A., Fléjou, J.F., Barthélémy, P. Second-line treatment for failure to eradicate *Helicobacter pylori* : a randomized trial comparing four treatment strategies. *Alimentary Pharmacology & Therapeutics* 2003; 18: 791-797. (IF 3.434)
29. Leodolter, A., Vaira, D., Bazzoli, F., Schutze, K., Hirschl, A., Mégraud, F., Malfertheiner, P. European multicentre validation trial of two new non-invasive tests for the detection of *Helicobacter pylori* antibodies : urine-based ELISA and rapid urine test. *Alimentary Pharmacology & Therapeutics* 2003; 18: 927-931. (IF 3.434)

30. Marais, A., Bilardi, C., Cantet, F., Mendz, G.L., Mégraud, F. Characterization of the genes *rdxA* and *frxA* involved in metronidazole resistance in *Helicobacter pylori*. *Research in Microbiology* 2003; 154: 137-144. (IF 2.426)
31. Gallay, A., Simon, F., Mégraud, F. Surveillance of human Campylobacter infections in France. Part 1. Which data ? A study of microbiological laboratories, 2000. *European Surveillance* 2003; 8: 213-217.
32. Gallay, A., Simon, F., Mégraud, F. Surveillance of human Campylobacter infections in France. Part 2. Implementation of national surveillance. *European Surveillance* 2003; 8: 218.
33. Mégraud, F. Les infections à Campylobacter en France (1986-2000). *Surveillance Nationale des Maladies Infectieuses* 1998-2000; Institut de Veille Sanitaire Saint Maurice: 133-135.
34. Mégraud, F. Surveillance de la résistance de *Helicobacter pylori* aux antibiotiques *Surveillance Nationale des Maladies Infectieuses* 1998-2000; Institut de Veille Sanitaire Saint Maurice: 327-329.

2004

35. Lehours, P., Dupouy, S., Bergey, B., Richy, F., Zerbib, F., Ruskoné-Fourmestreaux, A., Delchier, J.C., Mégraud, F., Ménard, A. Identification of two genetic markers of *Helicobacter pylori* strains involved in extranodal marginal zone B-cell lymphoma of MALT-type. *Gut* 2004; 53:931-937. (IF 7.692)
36. Matysiak-Budnik, T., Coffin, B., Lavergne-Slove, A., Sabate, J.M., Mégraud, F., Heyman, M. *Helicobacter pylori* increases the epithelial permeability to a food antigen in human gastric biopsies. *American Journal of Gastroenterology* 2004; 99: 225-232. (IF 5.116)
37. Lehours, P., Ménard, A., Dupouy, S., Bergey, B., Richy, F., Zerbib, F., Ruskoné-Fourmestreaux, A., Delchier, J.C., Mégraud, F. Evaluation of the association of nine *Helicobacter pylori* virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. *Infection and Immunity* 2004; 72: 880-888. (IF 3.933)
38. Kauser, F., Khan, A.A., Hussain, M.A., Carroll, I.M., Ahmad, N., Tiwari, S., Shouche, Y., Das, B., Alam, M., Ali, S.M., Habibullah, C.M., Sierra, R., Mégraud, F., Sechi, L.A., Ahmed, N. The *cag* pathogenicity island of *Helicobacter pylori* is disrupted in the majority of patient isolates from different human populations. *Journal of Clinical Microbiology* 2004; 42: 5302-5308. (IF 3.537)
39. Avenaud, P., Castroviejo, M., Claret, S., Rosenbaum, J., Mégraud, F., Ménard, A. Expression and activity of the cytolethal distending toxin of *Helicobacter hepaticus*. *Biochemical and Biophysical Research Communications* 2004; 318: 739-745. (IF 3)
40. Angelini, F., Ménard, A., Asencio, C., Marais, A., Mégraud, F. Construction of replicative and integrative plasmids for setting up the *in vivo* expression technology in *Helicobacter pylori*. *Plasmid* 2004; 51: 101-107. (IF 1.446)

41. Mégraud, F., Prouzet-Mauléon, V. Evolution de la résistance des *Campylobacters* aux antibiotiques en France (1986-2002). Bulletin Epidémiologique Hebdomadaire 2004; N° 32-33: 156-158.

2005

42. Rocha, M., Avenaud, P., Ménard, A., LeBail, B., Balabaud, C., Bioulac-Sage, P., de Magalhaes Queiroz, D.M., Mégraud, F. Association of *Helicobacter* species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut 2005; 54: 396-401. (IF 7.692)
43. Schaeferbeke, T., Broutet, N., Zerbib, F., Combe, B., Bertin, P., Lamouliatte, H., Perié, F., Joubert-Collin, M., Mégraud, F. Should we eradicate *Helicobacter pylori* before prescribing an NSAID ? Result of a placebo controlled study. American Journal of Gastroenterology 2005; 100: 2637-43 (IF 5.116)
44. Mamelli, L., Prouzet-Mauléon, V., Pagès, JM., Mégraud, F., Bolla, JM. Efflux *versus* Mutations: A molecular study of macrolide resistance in *Campylobacter*. Journal of Antimicrobial Chemotherapy 2005; 56: 491-7. (IF 3.886)
45. Prouzet-Mauléon, V., Abid Hussain, M., Lamouliatte, Farhana Kauser, H., Mégraud, F., Ahmed, N. Pathogen evolution *in vivo*: genome dynamics of two isolates obtained nine years apart from a duodenal ulcer patient infected with a single *Helicobacter pylori* strain. Journal of Clinical Microbiology 2005;43:4237-41.(IF 3.537)
46. Mégraud, F. (au nom de l'European Paediatric Task Force on *Helicobacter pylori*). Comparison of non-invasive tests to detect *Helicobacter pylori* infection in children and adolescents: results of a multicenter European study. Journal of Pediatrics 2005; 146: 198-203. (IF 1.382)
47. Ménard, S., Laharie, A., Asencio, C., Vidal-Martinez, T., Candahl, C., Rullier, A., Zerbib, F., Mégraud, F., Matysiak-Budnik, T., Heyman, M. *Bifidobacterium breve* and *Streptococcus thermophilus* secretion products enhance innate immunity and intestinal barrier in mice. Experimental Biology and Medecin 2005; 230: 749-56 (IF 2.851)
48. Pyndiah, S., Ménard, A., Zerbib, F., Mégraud, F. Evaluation of the homologous recombination processing in *Helicobacter pylori*. Helicobacter 2005; 10: 185-92 (IF 2.584)
49. de Mascarel, A., Ruskone-Fourmestreaux, A., Lavergne-Slove, A., Mégraud, F., Dubus, P., Merlio, J.P. Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. Virchows Archiv 2005; 446: 219-24. (IF 2.224).
50. Vacher S., Ménard, A., Bernard, E., Santos, A., Mégraud, F. Detection of mutations associated with macrolide resistance in thermophilic *Campylobacter* spp. by real-time PCR. Microbial Drug Resistance 2005;11:40-7. (IF 2.072)

51. Bergey, B., Gallian, P., Stuart M., Bolla, J.M., de Micco, P., Mégraud, F. Prévalence de l'infection à *Helicobacter pylori* en Corse. Gastroentérologie Clinique et Biologique 2005 ;29 :611-2. (IF 0.715).